Nyxoah (NYXH)

• Market cap: $220M
• 1 day: -0.84%
• 5 days: -3.29%
• 1 month: -48.19%
• 3 months: -45.80%
• 6 months: -39.48%
• Year to date: -35.07%
• 1 year: -48.01%
• 5 years: -80.50%
• 10 years: -80.50%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Employees: 184

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

60% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 5

39% more capital invested

Capital invested by funds: $39.1M [Q3] → $54.4M (+$15.3M) [Q4]

10% more funds holding

Funds holding: 20 [Q3] → 22 (+2) [Q4]

7.77% more ownership

Funds ownership: 11.95% [Q3] → 19.72% (+7.77%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $14 139% upside
• Avg. target: $14.50 147% upside
• High target: $15 156% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Stifel Jonathan Block 15% 1-year accuracy 3 / 20 met price target	139% upside $14	Buy Maintained	21 Apr 2025
HC Wainwright & Co. Edward White 21% 1-year accuracy 31 / 149 met price target	156% upside $15	Buy Reiterated	8 Apr 2025